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Indole-3-carbinol suppresses NF-B and IBkinase activation, causing
inhibition of expression of NF-B–regulated antiapoptotic and metastatic gene
products and enhancement of apoptosis in myeloid and leukemia cells
Yasunari Takada, MichaelAndreeff, and Bharat B.Aggarwal
Indole-3-carbinol, found in Brassica spe-
cies vegetables (such as cabbage, cauli-
ﬂower, and brussels spouts), exhibits an-
titumor effects through poorly deﬁned
mechanisms. Because several genes that
regulate apoptosis, proliferation, and me-
tastasis are regulated by nuclear fac-
tor-B (NF-B), we postulated that indole-
3-carbinol must mediate its activity
through NF-B modulation. We demon-
strated that indole-3-carbinol suppressed
constitutive NF-B activation and activa-
tion induced by tumor necrosis factor
(TNF), interleukin-1 (IL-1), phorbol 12-
myristate 13-acetate (PMA), lipopolysac-
charide (LPS), and cigarette smoke; the
suppression was not cell type speciﬁc,
because activation was inhibited in my-
eloid, leukemia, and epithelial cells. This
activation correlated with the sequential
suppression of the IB kinase, IB
phosphorylation, IB ubiquitination,
IB degradation, p65 phosphorylation,
p65 nuclear translocation, p65 acetyla-
tion, and NF-B–dependent reporter gene
expression. The NF-B–regulated gene
products cyclin D1, cyclooxygenase-2
(COX-2), matrix metalloproteinase-9
(MMP-9), survivin, inhibitor-of-apoptosis
protein-1 (IAP1), IAP2, X chromosome–
linked IAP (XIAP), Bcl-2, Bﬂ-1/A1, TNF
receptor-associatedfactor-1(TRAF1),and
Fas-associated death domain protein–
like interleukin-1–converting enzyme in-
hibitory protein (FLIP) were all down-
regulatedbyindole-3-carbinol.Thisdown-
regulation led to the potentiation of
apoptosis induced by cytokines and che-
motherapeutic agents. Indole-3-carbinol
suppressed constitutive NF-B activation
in mononuclear cells derived from bone
marrow of acute myelogenous leukemia
patients, and this correlated with inhibi-
tion of cell growth. Overall, our results
indicated that indole-3-carbinol inhibits
NF-BandNF-B–regulatedgeneexpres-
sion and that this mechanism may pro-
vide the molecular basis for its ability to
suppress tumorigenesis. (Blood. 2005;
106:641-649)
© 2005 by TheAmerican Society of Hematology
Introduction
Indole-3-carbinol (I3C) is an autolysis product of a glucosinolate,
glucobrassicin, found in Brassica species or cruciferous vegetables
(cabbage, broccoli, cauliﬂower, and brussels spouts).1,2 In vitro,
I3C was found to suppress the proliferation of various tumor cells,
including breast,3 prostate,4 colon,5 and endometrial cancer cells. In
most cells, I3C induces G1/S cell cycle arrest.6 In vivo, I3C has
been shown to suppress tumorigenesis of the colon,7,8 lung,9-11
breast,12 cervix,13,14 and liver.15
This molecule has been found to be effective clinically in
treating precancerous lesions of the cervix and laryngeal papillo-
mas, both of which have a human papillomavirus (HPV) compo-
nent to their etiologies.16-19 I3C has also been shown to alter
immune function,7,20 inhibit cigarette smoke–induced DNA-adduct
formation,21 and reverse multidrug resistance in vivo. Rats fed I3C
daily for 7 weeks had signiﬁcantly reduced natural killer cell
activity and elevated T-cell–mediated delayed-type hypersensitiv-
ity but no change in antibody production.20
Numerous reports indicate that I3C mediates its effects through
alteration of gene expression in different cells.22 This indole
down-regulates the expression of various genes, including induc-
ible nitric oxide synthase (iNOS),23 cyclin-dependent kinase 6
(CDK6),3,6 prostate-speciﬁc antigen (PSA),24 and Bcl-2.4 It has also
been shown to inhibit Akt25 and CDK6 expression in human
MCF-7 breast cancer cells by disrupting Sp1 transcription factor
interactions with a composite element in the CDK6 gene pro-
moter.26 That I3C directly binds to estrogen receptor-,27-30 aryl
hydrocarbon (Ah) receptor,31 and androgen receptor 32 has been
reported. Besides antiproliferative and immunomodulatory effects,
I3C also has been demonstrated to suppress the invasion and
migration of human breast cancer cells.29,33
Although this wide range of activities has been assigned to I3C,
its basic mechanism of action remains unclear. Based on the
conﬂuence of pathways affected by I3C and nuclear factor-B
(NF-B), we postulated that I3C interferes with the NF-B
activation pathway to exert its effects on gene expression. For
example, several genes that mediate proliferation, apoptosis, and
metastasis are regulated by NF-B.34 This transcription factor is
activated by various carcinogens and inﬂammatory stimuli, includ-
ing cigarette smoke, tumor necrosis factor (TNF), interleukin-1
(IL-1), receptor of receptor activator of NF-B ligand (RANKL),
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(LPS). NF-B consists of p50 and p65 heterodimer retained in the
cytoplasm by masking nuclear localization signal (NLS) by IB,
the inhibitor. On activation, IB kinase (IKK) is activated,
leading to IB phosphorylation, ubiquitination, and degradation,
thus releasing p50-p65 to translocate to the nucleus, bind to its
consensus sequence, and induce gene transcription. Although
NF-B activation has been shown to regulate apoptosis and
proliferation in leukemic cells,35-37 there is no report on the effect of
I3C in these cells. Therefore, the aim of the current study was to
investigate the effect of I3C on the NF-B activation pathway and
on apoptosis in leukemic cells.
Materials and methods
Reagents
I3C was purchased from Sigma-Aldrich (St Louis, MO).A50 mM solution
was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), stored as
small aliquots at 20°C, and then thawed and diluted as needed in cell
culture medium as described.4,6 No loss of activity of I3C was noted after
storage for 6 months. Throughout, 0.1% DMSO (equivalent to 50 M I3C)
was used as control. Bacteria-derived human recombinant TNF, puriﬁed to
homogeneity with a speciﬁc activity of 5  107 U/mg, was kindly provided
by Genentech (South San Francisco, CA). Bacteria-derived human recom-
binant IL-1, puriﬁed to homogeneity with a speciﬁc activity of 1.0 EU/g,
was purchased from R&D Systems (Minneapolis, MN). Cigarette smoke
condensate (CSC), prepared as described,38 was kindly supplied by Dr G.
Gairola (University of Kentucky, Lexington, KY). Doxorubicin was kindly
provided by Dr Waldemar Priebe (M. D. Anderson Cancer Center, The
University of Texas, Houston). Penicillin, streptomycin, RPMI 1640,
Iscove modiﬁed Dulbecco medium (IMDM), Dulbecco modiﬁed Eagle
medium (DMEM), nonessential amino acids, pyruvate, glutamine, vita-
mins, and fetal bovine serum (FBS) were obtained from Invitrogen (Grand
Island, NY). PMA, LPS, okadaic acid, H2O2, cisplatin, anti–-actin
antibody, and basic chemical reagents were obtained from Sigma-Aldrich.
Antibodies against p65, p50, IB, cyclin D1, matrix metalloproteinase-9
(MMP-9), poly(adenosine diphosphate-ribose) polymerase (PARP), inhibi-
tor-of-apoptosisprotein-1(IAP1),IAP2,Bcl-2,Bﬂ-1/A1,andTNFreceptor-
associated factor-1 (TRAF1) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti–cyclooxygenase-2 (anti–COX-2) and anti–X chro-
mosome–linked IAP (anti-XIAP) antibodies were obtained from BD
Biosciences (San Diego, CA). Phosphospeciﬁc anti-IB (Ser32) and
anti–acetyl-lysine antibodies were purchased from Cell Signaling Technol-
ogy (Beverly, MA). Anti–IKK-, anti–IKK-, and anti–Fas-associated
death domain protein–like interleukin-1–converting enzyme inhibitory
protein (anti-FLIP) antibodies were kindly provided by Imgenex (San
Diego, CA).Apolyclonal antibody that recognizes the serine 529 phosphor-
ylated form of p65 was obtained from Rockland Laboratories (Gilbertsville,
PA). N-acetyl-leucyl-leucyl-norleucinal (ALLN) was purchased from Cal-
biochem (San Diego, CA).
Cell lines
Jurkat (human T-cell leukemia), KBM-5 (human myeloid), H1299 (human
lung adenocarcinoma), U266 (human multiple myeloma), A293 (human
embryonic kidney) and SCC-4 (human squamous cell carcinoma) cells
were obtained from American Type Culture Collection (Manassas, VA).
MM.1 (human multiple myeloma) cells were kindly provided by Dr Steven
T. Rosen (Robert H. Lurie Comprehensive Cancer Center, Feinberg School
of Medicine, Northwestern University, Chicago, IL). KBM-5 cells were
cultured in IMDM with 15% FBS; Jurkat, H1299, MM.1, and U266 cells
were cultured in RPMI 1640 medium with 10% FBS; A293 cells were
cultured in DMEM supplemented with 10% FBS; and SCC-4 cells were
cultured in DMEM containing 10% FBS, nonessential amino acids,
pyruvate, glutamine, and vitamins. All media were supplemented with 100
U/mLpenicillin and 100 g/mLstreptomycin.
Clinical samples
Bone marrow specimens from acute myelogenous leukemia (AML) pa-
tients with high (more than 70%) blast counts (Table 1) were obtained after
signed informed content, according to institutional guidelines. All studies
were approved by the Institutional Review Board at the University of Texas
M.D. Anderson Cancer Center, Houston, TX. Mononuclear cells were
puriﬁedbyFicoll-Hypaque(Sigma-Aldrich)density-gradientcentrifugation.
Electrophoretic mobility shift assay (EMSA)
To measure NF-B activation, we prepared the nuclear extracts and
performed electrophoretic mobility shift assay (EMSA) as described
previously.39 The dried gels were visualized and radioactive bands quanti-
tated by a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using
Imagequant software.
Western blot analysis
To determine the levels of protein expression in the cytoplasm or nucleus,
we prepared extracts and fractionated them by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) as described previously.39
IKK assay
To determine the effect of I3C on IKK activation, IKK assay was performed
by a method described previously.39 Brieﬂy, whole-cell extract was
prepared, incubated with anti–IKK- antibody, and precipitated immuno-
complex by proteinA/G–Sepharose beads (Pierce, Rockford, IL). Immuno-
complex was subjected for kinase assay using glutathione S-transferase
(GST)–IB (1-79) as substrate.
NF-B–dependent reporter gene expression assay
The effect of I3C on TNF- and TNF receptor-1 (TNFR1)–induced
NF-B–dependent reporter gene transcription was analyzed by secretory
Table 1. Clinical data on patients
Patient
no./sex Source Type
Cytogenetic
abnormality
FAB
category
Blast
%
Blasts in
BM, %
WBC count,
 109/L
1/M BM AML Miscellaneous M2 75 90 26.7
2/M BM Leukemia t(8;21) M2 90 95 60.0
3/M BM AML 21 M2 74 85 32.0
4/F PB AML Miscellaneous M4 92 95 24.7
5/M BM Leukemia Diploid M5b 82 80 68.9
6/M BM AML t(9;22) Blast crisis 82 95 47.7
7/F BM AML Miscellaneous M5b 85 45 106.1
8/M BM AML Miscellaneous M4 85 95 60.5
9/F BM AML Miscellaneous M4 90 90 116.7
10/M BM AML Pseudodiploid M0 71 45 32.6
FAB indicates French-American-British; BM, bone marrow; WBC, white blood cell; M, male; PB, peripheral blood; F, female.
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cells were transiently transfected with the NF-B–regulated SEAP reporter
construct, incubated with I3C, and then stimulated them with TNF. Cells
werealsocotransfectedwithTNFR1-expressingplasmids,andthenNF-B–
dependent SEAPexpression was monitored.
Immunoprecipitation of p65 for p65 acetylation
The effect of I3C on TNF-induced acetylation of p65 was examined as
described previously.40 Brieﬂy, whole-cell extract was prepared, incu-
bated with anti-p65 antibody, and precipitated immunocomplex by
protein A/G–Sepharose beads. Immunecomplex was subjected for
SDS-PAGE, and Western blot analysis was performed using anti–acetyl-
lysine antibody.
Immunocytochemistry for NF-B p65 localization
The effect of I3C on the nuclear translocation of p65 was examined by
immunocytochemistry as described previously.39 Brieﬂy, cells were ﬁxed
with paraformaldehyde, permeabilized with Triton X-100, blocked with
normal goat serum, incubated with rabbit polyclonal anti-p65 antibody,
incubatedwithgoatantirabbitimmunoglobulinG(IgG)–Alexa594(Molecu-
lar Probes, Eugene, OR), and counterstained for nuclei with Hoechst 33342
(Sigma-Aldrich).
Cytotoxicity assay
The effect of I3C on the cytotoxic effects of TNF was determined by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
uptake method as described.41 Brieﬂy, 5000 cells were seeded in triplicate
in a 96-well plate and treated as indicated. Thereafter, an MTT solution was
added, lysed, and then the optic density (OD) was measured at 570 nm.
TUNEL assay
We also assayed cytotoxicity by the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end-labeling (TUNEL) method as
described previously.39 Brieﬂy, cells were ﬁxed with paraformaldehyde,
permeabilized with Triton X-100, and incubated with an in situ cell death
detection reagent (RocheApplied Science, Indianapolis, IN).
Live and dead assay
Apoptosis was measured by the Live and Dead assay (Molecular Probes),
which determines intracellular esterase activity and plasma membrane
integrity, performed as described previously.39
Results
ThecurrentstudywasundertakentoinvestigatetheeffectofI3Con
the NF-B activation pathway, NF-B–regulated gene expression,
and apoptosis in leukemic cells. The concentration of I3C and
NF-B activators used and the time of exposure had minimal effect
on the viability of these cells (data not shown).
I3C blocks NF-B activation induced by TNF, PMA, IL-1, LPS,
and CSC
Because TNF, IL-1, PMA, LPS, and CSC are potent activators of
NF-B, perhaps by different mechanisms,38,42,43 we examined the
effect of I3C on the activation of NF-B by these agents in Jurkat
cells. Pretreatment of cells with I3C suppressed the activation of
NF-B induced by all 5 agents (Figure 1A). These results suggest
that the I3C acts at a step in the NF-B activation pathway that is
common to all 5 agents.
I3C inhibits TNF-dependent NF-B activation
in a time-dependent manner
Because TNF is one of the most potent activators of NF-B and the
mechanism of activation of NF-B is relatively well established,
we examined the effect of I3C on TNF-induced NF-B activation.
Jurkat cells were incubated with I3C for various times and then
exposed to TNF. I3C by itself did not activate NF-B, but
TNF-induced NF-B activation was inhibited by I3C at 24 hours
(Figure 1B). Under these conditions, cells treated with I3C were
fully viable.
Inhibition of NF-B activation by I3C is dose dependent
and is not cell type speciﬁc
Because distinct signal transduction pathways can mediate NF-B
induction in different cell types (for references, see Shishodia et
al44), we also investigated whether I3C could block TNF-induced
NF-B activation in Jurkat, KBM-5, and H1299 cells. Cells were
pretreated with different concentrations of I3C and then treated
with TNF. TNF activated NF-B in all cell types, and I3C inhibited
the activation in a dose-dependent manner (Figure 1C). The results
also indicate that 50 M I3C is needed for maximum suppression
of NF-B activation.
Figure 1. Effect of I3C on TNF-induced NF-B activation. (A) I3C blocks NF-B
activation induced by TNF, PMA, LPS, and CSC. Jurkat cells were preincubated with
50 M I3C for 24 hours; treated with 0.1 nM TNF and 10 g/mL LPS for 30 minutes;
treated with 100 ng/mL IL-1, 15 ng/mL PMA, and 1 g/mL CSC for 1 hour; and then
analyzed for NF-B activation as described in “Materials and methods.” (B) Jurkat
cells were preincubated at 37°C with 50 M I3C for the indicated times and then
treated with 0.1 nM TNF at 37°C for 30 minutes. Nuclear extracts were then prepared
and assayed for NF-B activation by EMSA. Cell viability was determined by the
trypan blue dye exclusion method. (C) I3C suppresses TNF-induced NF-Bi na
dose-dependent manner in Jurkat, KBM-5, and H1299 cells. Cells were incubated
with different concentrations of I3C for 24 hours, followed by an incubation with 0.1
nM TNF for 30 minutes. Nuclear extracts were then prepared and assayed for NF-B
activation by EMSA. (D) I3C inhibits constitutive NF-B activation. MM.1, U266, and
SCC-4 cells were incubated with different concentrations of I3C for 24 hours. Nuclear
extracts were then prepared and assayed for NF-B activation by EMSA.
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in a dose-dependent manner
Whether I3C could suppress constitutive NF-B activation was
also examined. We treated human multiple myeloma MM.1 and
U266 cells and squamous cell carcinoma SCC-4 cells, which are
known to express constitutive active NF-B,36,37,45 with various
concentrations of I3C. Constitutive NF-B activation was sup-
pressed above 50 M (Figure 1D).
We have shown that high concentrations of TNF induce NF-B
more intensely than lower doses given for long times,46 so we
decided to establish TNF dose effects for I3C inhibition. TNF at a
concentration of 10 nM activated NF-B activity strongly; how-
ever, cells pretreated with I3C abolished TNF-induced NF-B
activation (data not shown). These results show that I3C is a very
potent inhibitor of TNF-induced NF-B activation.
To determine whether I3C directly modiﬁes the binding of the
NF-B complex to the DNA, we incubated nuclear extracts from
TNF-treated cells with various concentrations of I3C and then
analyzed DNA binding activity by EMSA. Our results show that
I3C did not modify the DNAbinding ability of the NF-B complex
(data not shown). We conclude that I3C inhibits NF-B activation
through an indirect mechanism.
Various combinations of Rel/NF-B protein constitute active
NF-B heterodimers that bind to a speciﬁc DNA sequence.47 To
show that the retarded band visualized by EMSA in TNF-treated
cells was indeed NF-B, we incubated nuclear extracts from
TNF-stimulated cells with antibodies to either the p50 (NF-B1) or
the p65 (RelA) subunit of NF-B. Both shifted the band to a higher
molecular mass (data not shown), thus suggesting that the TNF-
activated complex consisted of p50 and p65 subunits. Neither
preimmune serum nor the irrelevant antibody anticyclin D1 had
any effect. Excess unlabeled NF-B (100-fold) caused complete
disappearance of the band, but a mutant oligonucleotide of NF-B
did not affect NF-B binding activity.
I3C inhibits TNF-dependent IB degradation
To determine whether I3C’s inhibitory activity was due to inhibi-
tion of IB degradation, we pretreated cells with I3C, exposed
them to TNF for various times, and examined them for NF-B
activation in the nucleus by EMSA and for IB status in the
cytoplasm by Western blot analysis. NF-B was progressively
activated with increase in incubation times with TNF. The I3C-
pretreated cells showed a dramatic decrease in activation of NF-B
even after 60 minutes of TNF stimulation (Figure 2A).
The translocation of NF-B to the nucleus is preceded by the
proteolytic degradation of IB.47 We found that TNF induced
IB degradation in control cells within 10 minutes, but in
I3C-pretreated cells TNF had no effect on IB degradation
(Figure 2B). These results indicate that I3C inhibits both TNF-
induced NF-B activation and IB degradation.
I3C inhibits TNF-dependent IB phosphorylation
To determine whether inhibition ofTNF-induced IB degradation
was due to inhibition of IB phosphorylation, we pretreated cells
with I3C, exposed them to TNF for various times, and then
examined them for IB phosphorylation status in the cytoplasm
by Western blot analysis using antibody that recognizes the
serine-phosphorylated form of IB. Figure 2C shows that TNF-
induced IB phosphorylation was almost completely suppressed
by I3C.
I3C inhibits TNF-dependent IB ubiquitination
Phosphorylation of IB by TNF leads to ubiquitination and
degradation of IB.47 To investigate whether I3C affects TNF-
induced IB ubiquitination, we performed Western blot analysis.
We used the proteasome inhibitor ALLN to block the degradation
of IB.48 TNF treatment alone slightly induced ubiquitination of
IB, but when cells were pretreated with ALLN, TNF-induced
ubiquitination of IB was enhanced (Figure 2D). I3C almost
completely suppressed IB ubiquitination induced by TNF, even
in the presence of the proteasome inhibitor.
I3C inhibits TNF-induced IKK activation
It has been shown that IKK is required for TNF-induced phosphor-
ylation of IB.47 Because I3C inhibits the phosphorylation of
IB, we determined its effect on TNF-induced IKK activation. In
immunecomplex kinase assays, TNF activated IKK as early as 5
minutes after TNF treatment, but I3C completely suppressed this
Figure 2. Effect of I3C on IB phosphorylation and degradation induced by TNF. (A) I3C inhibits TNF-induced activation of NF-B. Jurkat cells were incubated with 50
M I3C for 24 hours, treated with 0.1 nM TNF for indicated times, and then analyzed for NF-B activation by EMSA. (B) Effect of I3C on TNF-induced degradation of IB.
Jurkat cells were incubated with 50 M I3C for 24 hours and treated with 0.1 nM TNF for the indicated times. Cytoplasmic extracts were prepared, fractionated on 10%
SDS-PAGE, and electrotransferred to nitrocellulose membrane. Western blot analysis was performed with anti-IB antibody. Anti–-actin antibody was the loading control.
(C) Effect of I3C on the phosphorylation of IB by TNF. Jurkat cells were incubated with of 50 M I3C for 24 hours and treated with 0.1 nM TNF for the indicated times.
Cytoplasmic extracts were fractionated and then blotted using phosphospeciﬁc anti-IB antibody. (D) Effect of I3C on TNF-induced ubiquitination of IB. Jurkat cells were
pretreated with 50 M I3C for 24 hours, then with 100 g/mL N-acetyl-leucyl-leucyl-norleucinal (ALLN) for 1 hour, and ﬁnally with 0.1 nM TNF for 15 minutes. Whole-cell
extracts were prepared, fractionated, and examined by Western blot analysis using anti-IB antibody. (E) Effect of I3C on the activation of IKK by TNF. Jurkat cells were
incubated with 50 M I3C for 24 hours and then activated with 1 nM TNF for different times. Whole-cell extracts were immunoprecipitated with antibody against IKK- and
analyzed by immunocomplex kinase assay. To examine the effect of I3C on the level of expression of IKK proteins, whole-cell extracts were fractionated on SDS-PAGE and
examined by Western blot analysis using anti–IKK- and anti–IKK- antibodies.
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expression of IKK- or IKK- proteins.
To evaluate whether I3C suppresses the IKK activity directly by
binding to the IKK protein or by suppressing the activation of IKK,
we incubated whole-cell extracts from untreated and TNF-treated
cells with various concentrations of I3C. Immunecomplex kinase
assay showed that I3C did not directly bind IKK, suggesting that
I3C modulates TNF-induced IKK activation (data not shown).
I3C inhibits TNF-induced nuclear translocation of p65
in lymphoma cells
TNF induces the phosphorylation of p65, which is required for
its transcriptional activity.49 Following phosphorylation, the p65
subunit is translocated to the nucleus. As shown in Figure 3A,
TNF induced phosphorylation of p65 in a time-dependent
manner; as early as 5 minutes after TNF stimulation, p65 was
phosphorylated and its levels in the cytoplasm increased up to
30 minutes. On pretreatment of cells with I3C, TNF failed to
induce phosphorylation of p65. We also showed that I3C
suppressed TNF-induced nuclear translocation of p65 in a
time-dependent manner (Figure 3B).
The acetylation of p65 plays a key role in NF-B transcriptional
activity.50 To examine the effect of I3C on the acetylation of p65 by
TNF, cells were pretreated with I3C and then treated with TNF for
the indicated times. Whole-cell extracts were prepared and immu-
noprecipitated with anti-p65 antibody, and then Western blot
analysis was performed using anti–acetyl-lysine antibody.Whereas
TNF induced acetylation of p65 in a time-dependent manner, I3C
suppressed it (Figure 3C).
An immunocytochemistry assay conﬁrmed the effect of I3C on
the suppression of nuclear translocation of p65: In untreated cells
p65 localized in the cytoplasm, TNF induced its nuclear transloca-
tion, and I3C clearly suppressed this translocation (Figure 3D).
I3C represses TNF-induced NF-B–dependent reporter
gene expression
Although we have shown by EMSA that I3C blocks NF-B
activation, DNA binding alone does not always correlate with
NF-B–dependent gene transcription, suggesting that there are
additional regulatory steps.51 TNF-induced NF-B activation is
mediated through sequential interaction of the TNF receptor. To
determine the effect of I3C on TNF-induced NF-B–dependent
reporter gene expression, we transiently transfected the cells with
the NF-B–regulated SEAP reporter construct, incubated them
with I3C, and then stimulated them with TNF. Cells were also
cotransfected with TNFR1-expressing plasmids, and then NF-B–
dependent SEAP expression was monitored. As shown in Figure
4A, cells showed NF-B–regulated reporter gene expression
whether they were activated with TNF or transfected with TNFR1
plasmid, but I3C suppressed activation.
Figure 4. I3C inhibits the TNF-induced expression of NF-B–dependent genes.
(A) I3C inhibits the NF-B–dependent reporter gene expression induced by TNF and
TNFR1. A293 cells were transiently transfected with an NF-B–containing plasmid
alone or with TNFR1-expressing plasmids for 24 hours.After transfection, cells were
washed and treated with the indicated concentrations of I3C for 24 hours. For
TNF-treated cells, cells were washed and treated with 1 nM TNF for an additional 24
hours. The supernatants of the culture medium were assayed for SEAP activity as
described in “Materials and methods.” Values represent the mean  SD of triplicate
cultures. (B) I3C inhibits TNF-induced cyclin D1, COX-2, and MMP-9 expression.
Jurkat cells were incubated with 25 M I3C and then treated with 1 nM TNF for the
indicated times. Whole-cell extracts were prepared and analyzed by Western blot
analysis using antibodies against cyclin D1, COX-2, and MMP-9. (C) I3C inhibits the
expression of TNF-induced antiapoptotic proteins. Jurkat cells were incubated with
25 M I3C and then treated with 1 nMTNF for the indicated times. Whole-cell extracts
were prepared and analyzed by Western blot analysis using antibodies against
survivin, IAP1, IAP2, XIAP, Bcl-2, Bﬂ-1/A1, TRAF1, FLIP, and -actin.
Figure3.EffectofI3ContheTNF-inducedtranslocationofp65intothenucleus.
(A) Western blot analysis of phospho-p65 and p65 using cytoplasmic extracts (CE).
Jurkat cells were incubated with 50 M I3C for 24 hours and treated with 0.1 nM TNF
for the indicated times in minutes. Cytoplasmic extracts were prepared and subjected
to Western blot analysis using anti-p65 antibody and phosphospeciﬁc anti-p65
antibody. (B) Western blot analysis of phospho-p65 and p65 using nuclear extracts
(NE). Jurkat cells were incubated with 50 M I3C for 24 hours and treated with 0.1 nM
TNF for the indicated times. Nuclear extracts were prepared and subjected to
Western blot analysis using anti-p65 and phosphospeciﬁc anti-p65 antibodies. For
loading control of nuclear protein, the membrane was blotted with anti-PARP
antibody. (C) Effect of I3C on TNF-induced acetylation of p65. Jurkat cells were
incubated with 50 M I3C for 24 hours and then treated with 1 nM TNF for the
indicated times. Whole-cell extracts were prepared, immunoprecipitated (IP) with
anti-p65antibody,andthenexaminedbyWesternblotanalysis(WB)usinganti–acetyl-
lysine antibody. Whole-cell extracts were subjected to Western blot analysis using
anti-p65 antibody. (D) Immunocytochemical analysis of p65 localization after treat-
ment with 1 nM TNF in the absence or presence of 50 M I3C. Jurkat cells were
incubated with I3C for 24 hours and then treated with 1 nM TNF for 30 minutes. Cells
were subjected to immunocytochemistry as described in “Materials and methods.”
Stained slides were mounted with mounting medium (Sigma-Aldrich) and analyzed
under an epiﬂuorescence microscope (Labophot-2; Nikon, Tokyo, Japan). Pictures
were captured using a Photometrics Coolsnap CF color camera (Nikon, Lewisville,
TX) and MetaMorph Version 4.6.5 software (Universal Imaging, Downingtown, PA).
Original magniﬁcation, 200.
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gene products COX-2, cyclin D1, and MMP-9 Whether I3C can
modulate certain NF-B–regulated gene products induced by TNF
was also examined. That COX-2, cyclin D1, and MMP-9 expres-
sion are regulated by NF-B has been reported.34 TNF has been
shown to induce cyclin D1, COX-2, and MMP-9, which have an
NF-B binding site in their promoter. Western blot analysis of
whole-cell extracts showed that TNF induced cyclin D1,
COX-2, and MMP-9 expression in a time-dependent manner and
I3C blocked these expressions (Figure 4B). The results further
support the role of I3C in blocking TNF-induced NF-B–
regulated gene products.
I3C represses TNF-induced NF-B–dependent antiapoptotic
gene products
NF-B regulates the expression of the antiapoptotic proteins
survivin, inhibitor-of-apoptosis protein-1/2 (IAP1/2), X chromo-
some–linked inhibitor-of-apoptosis protein (XIAP), Bcl-2, Bﬂ-
1/A1, TRAF1, and FLIP.34 Whether I3C can modulate the
expression of these antiapoptotic gene products induced by TNF
was also examined. As shown in Figure 4C, TNF induced these
antiapoptotic proteins in a time-dependent manner, and I3C
blocked this induction.
I3C potentiates apoptosis induced by TNF
and chemotherapeutic agents
The activation of NF-B has been shown to inhibit TNF-induced
apoptosis.52 Results from Figure 4C suggest the potential of I3C in
enhancing apoptosis induced by TNF and other cytotoxic agents
through suppression of NF-B–regulated antiapoptotic gene prod-
ucts. Whether suppression of NF-B by I3C affects TNF-induced
apoptosis was investigated by MTT, PARP cleavage, Live and
Dead assay, and TUNEL staining methods. I3C enhanced TNF-
induced cytotoxicity (Figure 5A1) as well as doxorubicin- (Figure
5A2) and cisplatin-induced cytotoxicity (Figure 5A3). I3C by itself
had little cytotoxic effect. Whether enhanced cytotoxicity was due
to apoptosis was further investigated.As shown in Figure 5B, TNF
activated caspases as indicated by PARP cleavage, and I3C
potentiated TNF-induced activity. The Live and Dead assay
indicated that I3C up-regulates TNF-induced apoptosis from 7% to
53% (Figure 5C), and TUNEL staining showed that TNF-induced
apoptosis was enhanced from 8% with TNF alone to 64% with I3C
plus TNF (Figure 5D). In this assay I3C alone exhibited signiﬁcant
toxicity. Nevertheless, all assays together suggest that I3C en-
hanced the apoptotic effects of TNF and chemotherapeutic agents.
I3C inhibits constitutive NF-B activation and proliferation
of mononuclear cells derived from AML patients
It has been reported that NF-B is constitutively active in AML
cells53 and that the active NF-B mediates proliferation of cells.35
Whether I3C could suppress constitutively active NF-B in AML
cells was investigated in AML cells derived from 10 different
patients (Table 1). The cells were treated with I3C, nuclear extracts
were prepared, and then NF-B activity was analyzed by EMSA.
As shown in Figure 6A, NF-B was found to be active in AML
cells from most patients, though to variable extents, and I3C
suppressed the activation.We also found that the treatment ofAML
cells with I3C decreased the proliferation of cells (Table 2).
Discussion
We found that I3C suppressed NF-B activation induced by
various agents irrespective of the cell type. NF-B inhibition
correlated with suppression of IKK and IB phosphorylation,
ubiquitination, and degradation and with p65 phosphorylation,
nuclear translocation, and acetylation. I3C also down-regulated
NF-B–regulated reporter gene transcription and gene products
involved in cell proliferation, antiapoptosis, and invasion. This led
to the potentiation of apoptosis induced by cytokines and chemo-
therapeutic agents (Figure 7).
I3C inhibited NF-B activation induced by TNF, IL-1, PMA,
LPS, and CSC, suggesting that I3C must act at a step common to all
of these activators. In response to most of these stimuli, NF-B
activationproceedsthroughsequentialactivationofIKK,phosphor-
ylation at serines 32 and 36 of IB, and ubiquitination at lysines
21 and 22 of IB, leading ﬁnally to degradation of IB and the
release of NF-B.47 We found that I3C blocks NF-B activation by
inhibiting IKK.
Suppression of TNF-induced NF-B activation by I3C is
consistent with a report by Chinni et al,4 who showed the
Figure 5. I3C enhances TNF-induced cytotoxicity. (A) I3C enhances TNF- and
chemotherapy-induced cytotoxicity. A total of 5000 Jurkat cells were seeded in
triplicate in 96-well plates. Cells were pretreated with 1 M I3C and then incubated
with indicated concentrations of TNF (i), cisplatin (ii), or doxorubicin (iii) for 72 hours.
Thereafter, cell viability was analyzed by the MTT method as described in “Materials
and methods.” Values represent the mean  SD of triplicate cultures. (B) Jurkat cells
were pretreated with 25 M I3C and then incubated with 1 nM TNF for the indicated
times. Whole-cell extracts were prepared, subjected to SDS-PAGE, and blotted with
anti-PARP antibody. (C) Jurkat cells were pretreated with 25 M I3C and then
incubated with 1 nM TNF for 16 hours. Cells were stained with Live and Dead assay
reagent for 30 minutes and then analyzed under a ﬂuorescence microscope as
described in “Materials and methods.” (D) Jurkat cells were pretreated with 25 M
I3C and then incubated with 1 nM TNF for 16 hours. Cells were ﬁxed, stained with
TUNEL assay reagent, and then analyzed under a ﬂuorescence microscope as
described in “Materials and methods.” Stained slides were mounted with mounting
medium (Sigma-Aldrich) and analyzed under an epiﬂuorescence microscope (Labo-
phot-2; Nikon). Pictures were captured using a Photometrics Coolsnap CF color
camera (Nikon, Lewisville, TX) and Meta Morph version 4.6.5 software (Universal
Imaging). Original magniﬁcation, 200.
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however, report how I3C suppressed constitutive NF-B activa-
tion. Howells et al54 found that the breast cancer cell lines
MDA-MB468 and HBL-100 express constitutive NF-Ba s
examined by DNA binding and that treatment with I3C de-
creases DNA binding in MDA-MB468 cells and increases it in
HBL-100 cells without changing IKK activity in either cell line.
They used up to 20 times (1 mM) the concentration of I3C as we
did to suppress NF-B. It is unlikely that these differences are
due to cell type, because we found that I3C suppressed
TNF-induced NF-B activation in all cell types tested. Perhaps
the mechanism of constitutive NF-B activation differs from
that of inducible activation examined in our studies.
Our studies are the ﬁrst to indicate that I3C also inhibits
TNF-induced IKK activation. How IKK is activated is not fully
understood, but Akt has been implicated,55 and I3C has been
shown to suppress Akt activation.25,54 Thus, it is possible that
inhibition of TNF-induced IKK activation is due to inhibition of
Akt. The activation ofAkt has also been shown to be involved in
the phosphorylation of the p65 subunit of NF-B.55 The
suppression of p65 phosphorylation by I3C could also be due to
inhibition ofAkt.
We showed that I3C inhibited NF-B–regulated gene transcrip-
tion and NF-B–regulated gene products involved in cell prolifera-
tion (eg, cyclin D1 and COX-2), antiapoptosis (eg, survivin, IAP1,
IAP2, XIAP, Bcl-2, Bﬂ-1/A1, TRAF1, and FLIP), and invasion
(MMP-9). There is no previous report of the regulation of these
gene products by I3C. That I3C down-regulates cyclin D1 expres-
sion and the latter mediates G1/S transition may explain reports
indicating that I3C induces G1/S arrest.3,4 The down-regulation of
the expression of iNOS,23 PSA,12 and Bcl-2 4 could also be due to
down-regulation of NF-B as described here.
We found that I3C potentiates the apoptotic effects of cytokines
and chemotherapeutic agents through the down-regulation of the
antiapoptosis gene products survivin, IAP1, IAP2, XIAP, Bcl-2,
Bﬂ-1/A1, TRAF1, and FLIP. The cytotoxic effects of TNF,
cisplatin, and doxorubicin were enhanced by I3C. These results are
in agreement with a report that pretreatment with I3C augments
TRAIL-induced apoptosis in the prostate cancer cell line LNCaP,
as measured by PARP and caspase-3 cleavage.56 Our results are
also consistent with a report that an I3C acid-condensation product
mixture sensitizes multidrug resistance gene transfectants to the
toxicity of vinblastine and doxorubicin.57 Whether enhancement of
apoptosis by I3C is also mediated through this mechanism, in
addition to down-modulation of NF-B, is unclear at present.
We also found that the expression of such NF-B–regulated
gene products as COX-2 and MMP-9 were down-regulated by
I3C. These results might explain the antiinvasive and antimeta-
static activities assigned to I3C.33,58 Several chemokines, inter-
leukins, and hematopoietic growth factors are regulated by
NF-B activation.43 It is possible that immunomodulatory
effects of I3C 7,20 are mediated through the regulation of these
cytokines. I3C has been found to prevent cervical cancer in
human HPV16 transgenic mice.13 Because a functional NF-B
binding site exists in the HPV16 long control region,59 it is
possible that its effects against cervical cancer are mediated
through suppression of NF-B as described here. Constitutively
Figure 6. I3C inhibits constitutively active NF-B activity and proliferation of
AML cells. A total of 1  107 cells were resuspended in RPMI 1640 medium and
treated with 50 M I3C for 24 hours, and nuclear extracts were prepared and then
analyzed for NF-B activity by EMSA.
Table 2. Relative cell viability, by I3C concentration
Patient
no.
Relative cell viability, %
0 M I3C 1 M I3C 2 M I3C 5 M I3C 10 M I3C 20 M I3C 30 M I3C
1 100  4.2 103  2.0 104  1.2 103  4.6 102  5.3 80  3.1 53  0.0
2 100  5.7 106  7.2 104  6.4 86  3.3 88  2.8 57  6.7 60  5.7
3 100  7.0 102  8.3 95  1.6 98  3.6 89  1.2 86  1.2 63  3.6
4 100  2.7 85  3.4 78  1.6 80  5.0 76  4.3 63  1.2 51  2.5
5 100  2.4 94  1.1 95  2.2 88  0.3 85  1.1 78  1.5 62  1.9
6 100  4.1 92  0.2 91  0.2 90  3.2 80  3.5 68  0.9 52  1.5
7 100  6.1 112  7.7 105  6.8 108  3.6 98  3.0 95  7.1 69  6.1
8 100  3.0 95  3.7 88  1.8 90  5.6 85  4.8 71  1.3 57  2.7
9 100  6.1 92  6.1 85  3.4 74  5.4 63  3.1 68  1.5 51  6.1
10 100  4.9 103  4.5 105  7.3 99  2.2 91  1.6 83  4.9 47  2.1
Atotal of 1  105 cells in RPMI 1640 were seeded in a 96-well plate, treated with the indicated concentrations of I3C for 72 hours, and then analyzed for cell viability by the
MTT method.
Figure 7. A schematic diagram of the effect of I3C on TNF-induced NF-B
activation and apoptosis.
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E7 level in laryngeal squamous cell carcinoma.60 Through sup-
pression of NF-B, I3C may also be effective against
this cancer.
Given the pharmacologic safety of I3C (established through
centuries of dietary intake), our studies suggest that this
compound has great potential as both a chemopreventive and a
chemotherapeutic agent, especially when used in combination
with existing agents. Whether the concentrations of I3C used in
our studies are achievable in vivo remains to be determined.
How I3C is metabolized in the cells is also unclear at present.
Our results also show that AML cells derived from patients
exhibit constitutive NF-B activation. This NF-B activation is
suppressed by I3C, thus leading to inhibition of proliferation of
the cells. Overall, our results demonstrate that I3C is a potent
inhibitor of NF-B activation, which may explain its antiprolif-
erative, proapoptotic, antimetastatic, anti-inﬂammatory, and
immunomodulatory effects.
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